CO5700789A2 - Composiciones inmunogenicas - Google Patents
Composiciones inmunogenicasInfo
- Publication number
- CO5700789A2 CO5700789A2 CO06034534A CO06034534A CO5700789A2 CO 5700789 A2 CO5700789 A2 CO 5700789A2 CO 06034534 A CO06034534 A CO 06034534A CO 06034534 A CO06034534 A CO 06034534A CO 5700789 A2 CO5700789 A2 CO 5700789A2
- Authority
- CO
- Colombia
- Prior art keywords
- spp
- virus
- antigen
- hepatitis
- immunogenic
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 abstract 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 abstract 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 abstract 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 abstract 1
- 241000588807 Bordetella Species 0.000 abstract 1
- 241000589968 Borrelia Species 0.000 abstract 1
- -1 CASB616 Proteins 0.000 abstract 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241001647372 Chlamydia pneumoniae Species 0.000 abstract 1
- 241000606153 Chlamydia trachomatis Species 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 241000588722 Escherichia Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 241000589989 Helicobacter Species 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000724675 Hepatitis E virus Species 0.000 abstract 1
- 241000709721 Hepatovirus A Species 0.000 abstract 1
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 abstract 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 abstract 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 abstract 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 abstract 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 102100034872 Kallikrein-4 Human genes 0.000 abstract 1
- 241000186781 Listeria Species 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 abstract 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 abstract 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 abstract 1
- 241000588621 Moraxella Species 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 108010008707 Mucin-1 Proteins 0.000 abstract 1
- 241000711386 Mumps virus Species 0.000 abstract 1
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 102000036673 PRAME Human genes 0.000 abstract 1
- 108060006580 PRAME Proteins 0.000 abstract 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 abstract 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 abstract 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 241000702670 Rotavirus Species 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract 1
- 108010002687 Survivin Proteins 0.000 abstract 1
- 108010017842 Telomerase Proteins 0.000 abstract 1
- 241000223996 Toxoplasma Species 0.000 abstract 1
- 102100039094 Tyrosinase Human genes 0.000 abstract 1
- 108060008724 Tyrosinase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 231100000249 enterotoxic Toxicity 0.000 abstract 1
- 230000002242 enterotoxic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108010024383 kallikrein 4 Proteins 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 abstract 1
- 108010079891 prostein Proteins 0.000 abstract 1
- 235000002020 sage Nutrition 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323968.8A GB0323968D0 (en) | 2003-10-13 | 2003-10-13 | Immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700789A2 true CO5700789A2 (es) | 2006-11-30 |
Family
ID=29559207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06034534A CO5700789A2 (es) | 2003-10-13 | 2006-04-07 | Composiciones inmunogenicas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070212328A1 (enExample) |
| EP (1) | EP1684802A2 (enExample) |
| JP (1) | JP2007508273A (enExample) |
| KR (1) | KR20060131749A (enExample) |
| CN (1) | CN1893974A (enExample) |
| AU (1) | AU2004283458A1 (enExample) |
| BR (1) | BRPI0415315A (enExample) |
| CA (1) | CA2541693A1 (enExample) |
| CO (1) | CO5700789A2 (enExample) |
| GB (1) | GB0323968D0 (enExample) |
| IL (1) | IL174542A0 (enExample) |
| IS (1) | IS8387A (enExample) |
| MA (1) | MA28106A1 (enExample) |
| NO (1) | NO20061911L (enExample) |
| RU (1) | RU2006111849A (enExample) |
| WO (1) | WO2005039630A2 (enExample) |
| ZA (1) | ZA200602948B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884083B2 (en) * | 2002-08-12 | 2011-02-08 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| EP1613274B1 (en) * | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| US20100061958A1 (en) * | 2006-09-14 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Modulation of Regulatory T Cells by Human IL-18 |
| SE532249C2 (sv) * | 2006-11-13 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering |
| CN101678091A (zh) | 2007-05-24 | 2010-03-24 | 葛兰素史密丝克莱恩生物有限公司 | 冷冻干燥的抗原组合物 |
| WO2009108235A2 (en) * | 2007-12-07 | 2009-09-03 | Tekmira Pharmaceuticals Corporation | Compositions and methods for modulating immune responses to nucleic acids |
| GB0810869D0 (en) * | 2008-06-13 | 2008-07-23 | Isis Innovation | Vaccine adjuvant composition |
| TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2202298A1 (en) | 2008-12-23 | 2010-06-30 | Stichting Dienst Landbouwkundig Onderzoek | Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV |
| EP2381949B1 (en) * | 2008-12-23 | 2012-11-21 | Intervet International BV | Immunostimulating saponins for use in in situ tumor-destruction therapy |
| US9566323B2 (en) * | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| CN101814489A (zh) * | 2010-03-02 | 2010-08-25 | 晶科电子（广州）有限公司 | 带有功能芯片的发光二极管封装结构及其封装方法 |
| EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US20130142878A1 (en) * | 2011-12-01 | 2013-06-06 | Flow Pharma, Inc. | Peptide particle formulation |
| US20140105970A1 (en) * | 2011-12-01 | 2014-04-17 | Flow Pharma, Inc. | Adjuvant and antigen particle formulation |
| SG11201500243WA (en) * | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| CN116327912A (zh) * | 2021-12-23 | 2023-06-27 | 上海泽润生物科技有限公司 | 带状疱疹疫苗组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016247A1 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| AU3827699A (en) * | 1998-05-07 | 1999-11-23 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| US20010044418A1 (en) * | 2000-03-10 | 2001-11-22 | Shoshana Levy | Treatment of allergies |
-
2003
- 2003-10-13 GB GBGB0323968.8A patent/GB0323968D0/en not_active Ceased
-
2004
- 2004-10-11 EP EP04790466A patent/EP1684802A2/en not_active Withdrawn
- 2004-10-11 CA CA002541693A patent/CA2541693A1/en not_active Abandoned
- 2004-10-11 CN CNA2004800372174A patent/CN1893974A/zh active Pending
- 2004-10-11 WO PCT/EP2004/011621 patent/WO2005039630A2/en not_active Ceased
- 2004-10-11 KR KR1020067009353A patent/KR20060131749A/ko not_active Withdrawn
- 2004-10-11 AU AU2004283458A patent/AU2004283458A1/en not_active Abandoned
- 2004-10-11 JP JP2006530156A patent/JP2007508273A/ja active Pending
- 2004-10-11 US US10/575,836 patent/US20070212328A1/en not_active Abandoned
- 2004-10-11 RU RU2006111849/14A patent/RU2006111849A/ru not_active Application Discontinuation
- 2004-10-11 BR BRPI0415315-4A patent/BRPI0415315A/pt not_active Application Discontinuation
-
2006
- 2006-03-23 IL IL174542A patent/IL174542A0/en unknown
- 2006-03-30 IS IS8387A patent/IS8387A/is unknown
- 2006-04-07 CO CO06034534A patent/CO5700789A2/es not_active Application Discontinuation
- 2006-04-11 ZA ZA200602948A patent/ZA200602948B/xx unknown
- 2006-04-25 MA MA28960A patent/MA28106A1/fr unknown
- 2006-04-28 NO NO20061911A patent/NO20061911L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070212328A1 (en) | 2007-09-13 |
| NO20061911L (no) | 2006-06-07 |
| RU2006111849A (ru) | 2007-11-20 |
| WO2005039630A2 (en) | 2005-05-06 |
| JP2007508273A (ja) | 2007-04-05 |
| ZA200602948B (en) | 2007-09-26 |
| WO2005039630A3 (en) | 2005-07-21 |
| EP1684802A2 (en) | 2006-08-02 |
| CN1893974A (zh) | 2007-01-10 |
| AU2004283458A1 (en) | 2005-05-06 |
| CA2541693A1 (en) | 2005-05-06 |
| KR20060131749A (ko) | 2006-12-20 |
| BRPI0415315A (pt) | 2006-12-05 |
| IS8387A (is) | 2006-03-30 |
| IL174542A0 (en) | 2006-08-01 |
| GB0323968D0 (en) | 2003-11-19 |
| MA28106A1 (fr) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512047A5 (enExample) | ||
| RU2006111849A (ru) | Иммуногенные композиции | |
| Karch et al. | Vaccine technologies: From whole organisms to rationally designed protein assemblies | |
| CO2018005258A2 (es) | Vacuna del virus herpes simple | |
| JP2007508273A5 (enExample) | ||
| CO5200838A1 (es) | Vacunas | |
| CO5700790A2 (es) | Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina | |
| WO2003009812A3 (en) | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | |
| ES2192582T3 (es) | Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado. | |
| CA2179779A1 (en) | Vaccine compositions comprising oil in water emulsions with tocopherol and squalene | |
| MXPA01007760A (es) | Compuesto adyuvante inmunologico. | |
| ES2150493T3 (es) | Adyuvantes para vacunas contra el virus sincitico respiratorio. | |
| HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
| WO2004084936A3 (en) | Modified free-living microbes, vaccine compositions and methods of use thereof | |
| PT2364724E (pt) | Composição de vacina compreendendo um adjuvante de saponina | |
| CY1112572T1 (el) | Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες | |
| CA2354046A1 (en) | New cancer treatments | |
| MX9401225A (es) | Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. | |
| CA2427475A1 (en) | Purification of hbv antigens for use in vaccines | |
| PE97298A1 (es) | Composicion para vacunas | |
| BR112023021812A2 (pt) | Composição vacinal adjuvantada e métodos | |
| MD20210028A2 (ro) | Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia | |
| Angulo et al. | Trained immunity-based Adjuvated vaccines (TIbAV) approach: β-glucans as example | |
| AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
| WO2001070932A3 (en) | Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |